Application of Isolated Organ Perfusion Techniques in Toxicology

2007 ◽  
pp. 1889-1946
Author(s):  
Luca Erlitz ◽  
Caleb Ibitamuno ◽  
Benedek Kasza ◽  
Vivien Telek ◽  
Péter Hardi ◽  
...  

BACKGROUND: The cold ischemia –reperfusion injury may lead to microcirculatory disturbances, hepatocellular swelling, inflammation, and organ dysfunction. Nicorandil is an anti-ischemic, ATP-sensitive potassium (KATP) channel opener drug and has proved its effectiveness against hepatic Ischemia/Reperfusion (I/R) injury. OBJECTIVE: This study aimed to investigate the effect of Nicorandil on mitochondrial apoptosis, oxidative stress, inflammation, histopathological changes, and cold ischemic tolerance of the liver in an ex vivo experimental isolated-organ-perfusion model. METHODS: We used an ex vivo isolated rat liver perfusion system for this study. The grafts were retrieved from male Wistar rats (n = 5 in each), preserved in cold storage (CS) for 2 or 4 hours (group 1, 2), or perfused for 2 or 4 hours (group 3, 4) immediately after removal with Krebs Henseleit Buffer (KHB) solution or Nicorandil containing KHB solution under subnormothermic (22–25°C) conditions (group 5, 6). After 15 minutes incubation at room temperature, the livers were reperfused with acellular, oxygenated solution under normothermic condition for 60 minutes. RESULTS: In the Nicorandil perfused groups, significantly decreased liver enzymes, GLDH, TNF-alpha, and IL-1ß were measured from the perfusate. Antioxidant enzymactivity was higher in the perfused groups. Histopathological examination showed ameliorated tissue deterioration, preserved parenchymal structure, decreased apoptosis, and increased Bcl-2 activity in the Nicorandil perfused groups. CONCLUSIONS: Perfusion with Nicorandil containing KHB solution may increase cold ischemic tolerance of the liver via mitochondrial protection which can be a potential therapeutic target to improve graft survival during transplantation.


1969 ◽  
Vol 27 (3) ◽  
pp. 403-406 ◽  
Author(s):  
R L Fisk ◽  
D F McFarlane ◽  
K Kowalewski ◽  
C M Couves

Gene Therapy ◽  
1997 ◽  
Vol 4 (1) ◽  
pp. 55-62 ◽  
Author(s):  
WK de Roos ◽  
FJ Fallaux ◽  
A W K S Marinelli ◽  
A Lazaris-Karatzas ◽  
B Alting von Geusau ◽  
...  

2004 ◽  
Vol 49 (11) ◽  
pp. 322-326 ◽  
Author(s):  
M Hexamer ◽  
U Schütt ◽  
H Knobl ◽  
R Körfer ◽  
J Werner

1971 ◽  
Vol 16 (1) ◽  
pp. 81-87 ◽  
Author(s):  
H. D. Ritchie ◽  
J. D. Hardcastle ◽  
J. Hermon-Taylor ◽  
A. D. W. Maclean

2016 ◽  
Vol 144 (11-12) ◽  
pp. 670-675 ◽  
Author(s):  
Stamenko Susak ◽  
Aleksandar Redzek ◽  
Milenko Rosic ◽  
Lazar Velicki ◽  
Bogdan Okiljevic

The idea of isolated organ perfusion, a precursor of cardiopulmonary bypass, came by Legalois in 1812. First isolated organ perfusion was described by Loebell in 1849. The first closed system for oxygenation and returning the blood through arteries was created by Frey and Gruber in 1885. Gibbon Jr. is considered the father of extracorporeal circulation. In spring of 1934 he began constructing a machine for extracorporeal circulation in Boston. He published the first description of this system in 1937. Gibbon won the grant of the International Business Machines Corporation for developing the machine in 1947. Together they developed Model I in 1949 and Model II in 1951. After a few unsuccessful attempts in 1952, the first successful surgical intervention on the heart (closure of atrial septal defect) using cardiopulmonary bypass was performed on May 6, 1953. In 1945, Kirklin and his working group reported on a series of eight successfully treated patients in a row who underwent surgery with extracorporeal circulation. First successful valve surgery under the direct vision was performed by Dodrill in 1952, using his ?Michigan Heart? machine as a right heart bypass. Using cardiopulmonary bypass, cardiac surgeons can deal with the complex cardiac pathology and save millions of lives.


1975 ◽  
Author(s):  
J. C. Giddings ◽  
E. Shaw ◽  
E. G. D. Tuddenham ◽  
A. L. Bloom

Human foetal tissues were maintained in tissue culture and the presence of factor V detected by an indirect immunofluorescence technique. Established monolayer cultures of human foetal liver cells showed positive immunofluorescence when treated with rabbit anti human factor V serum and fluorescein isothiocyanate conjugated with anti rabbit immunoglobulin. Parallel liver cultures containing cycloheximide did not show positive fluorescence when stained by the same technique.Hepatic factor V synthesis was also investigated by an ex-vivo organ perfusion method using adult rat livers. Factor V synthesis was most clearly demonstrated utilising leucocyte-and platelet-poor perfusate. Factor V synthesis was totally inhibited by cycloheximide and was inhibited by actinomycin D after an initial delay. Factor V synthesis was not inhibited by Warfarin.The results indicate that factor V is synthesised in the liver by a mechanism similar to that of other plasma proteins and is not dependant on vitamin K for its activity.


Copeia ◽  
1972 ◽  
Vol 1972 (2) ◽  
pp. 374
Author(s):  
James E. Turner ◽  
F. B. Leftwich

1979 ◽  
Vol 26 (2) ◽  
pp. 206-207
Author(s):  
Mark J. Falzone ◽  
William W. Barrie ◽  
Worthington G. Schenk

Sign in / Sign up

Export Citation Format

Share Document